U.S. COVID-19 Vaccination Challenges Go Beyond Supply.

Abstract

A trio of current Annals articles each takes a different route to the same conclusion, which is the use initial supplies of coronavirus disease 2019 (COVID-19) vaccines to immunize as many persons as possible with a single-dose regimen may achieve more benefit than a more effective 2-dose regimen in a smaller population The model of Paltiel et al makes the case for a single-dose vaccine, even if it is somewhat less effective than a 2-dose regimen of another vaccine Barnabas and Wald argue for single-dose immunization campaigns involving the Pfizer/BioNTech and Moderna vaccines, despite the absence of long-term efficacy data from clinical trials The model from Tuite et al questions the practice of reserving the second dose for every person immunized Supported by strong public health systems, rapid vaccine production, and equitable vaccine distribution within the US and around the world, vaccination strategies driven by data can bring an end to COVID-19